OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+109.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$510M
AUM Growth
+$510M
(+84%)
Cap. Flow
+$74.8M
Cap. Flow
% of AUM
14.68%
Top 10 Holdings %
Top 10 Hldgs %
42.94%
Holding
56
New
7
Increased
29
Reduced
8
Closed
9
Top Buys
| 1 |
APTO
Aptose Biosciences, Inc.
APTO
|
$19.1M |
| 2 |
Ocular Therapeutix
OCUL
|
$9.21M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$8.12M |
| 4 |
EDAP
EDAP TMS
EDAP
|
$6.58M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$6.43M |
Top Sells
| 1 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$8.04M |
| 2 |
Cytokinetics
CYTK
|
$7.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.79M |
| 4 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$2.93M |
| 5 |
NextCure
NXTC
|
$2.62M |
Sector Composition
| 1 | Healthcare | 90.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $34.1M | 6.68% | 1,384,200 +19,200 | +1% | +$472K |
|
|
APTO
2
DELISTED
Aptose Biosciences, Inc.
APTO
| $23.2M | 4.54% | 4,085,000 +3,365,000 | +467% | +$19.1M |
|
3
Codexis
CDXS
$246M
| $22.3M | 4.37% | 1,400,000 +50,000 | +4% | +$796K |
|
|
FTSV
4
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $22.1M | 4.34% | 562,000 +137,000 | +32% | +$5.39M |
|
5
Stereotaxis
STXS
$261M
| $22M | 4.32% | 4,112,500 +42,500 | +1% | +$228K |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $21.2M | 4.16% | 340,500 +53,000 | +18% | +$3.3M |
|
|
7
Ocular Therapeutix
OCUL
$2.12B
| $20.2M | 3.96% | 5,107,500 +2,332,500 | +84% | +$9.21M |
|
8
Harrow
HROW
$1.44B
| $18.2M | 3.57% | 2,340,000 -30,000 | -1% | -$233K |
|
|
EIDX
9
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $18.1M | 3.55% | 315,550 +10,000 | +3% | +$574K |
|
|
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
| $17.5M | 3.43% | 292,000 +7,000 | +2% | +$419K |
|
11
Neurogene
NGNE
$264M
| $17M | 3.34% | 1,381,300 +386,300 | +39% | +$4.76M |
|
12
uniQure
QURE
$896M
| $15M | 2.95% | 210,000 +5,000 | +2% | +$358K |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $14.3M | 2.8% | 665,000 +20,000 | +3% | +$429K |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14M | 2.74% | 224,500 -5,500 | -2% | -$342K |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14M | 2.74% | 406,600 +236,600 | +139% | +$8.12M |
|
|
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.8M | 2.72% | 361,600 +161,600 | +81% | +$6.19M |
|
17
Axogen
AXGN
$743M
| $12.5M | 2.46% | 700,000 | – | – |
|
18
Avalo Therapeutics
AVTX
$122M
| $11.8M | 2.32% | 2,190,674 +5,138 | +0.2% | +$27.7K |
|
|
ODT
19
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $11.5M | 2.26% | 355,000 +5,000 | +1% | +$162K |
|
20
Eton Pharmaceutcials
ETON
$464M
| $10.6M | 2.08% | 1,469,456 +304,456 | +26% | +$2.19M |
|
21
Xoma
XOMA
$392M
| $10.2M | 2% | 373,450 -1,550 | -0.4% | -$42.3K |
|
|
ATXI
22
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $9.94M | 1.95% | 1,035,000 +82,400 | +9% | +$791K |
|
23
PTC Therapeutics
PTCT
$3.92B
| $9.17M | 1.8% | 191,000 +1,000 | +0.5% | +$48K |
|
|
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.98M | 1.76% | 165,000 +5,000 | +3% | +$272K |
|
25
Acadia Pharmaceuticals
ACAD
$4.38B
| $8.83M | 1.73% | 206,500 +6,500 | +3% | +$278K |
|